NewAmsterdam Pharma
Presence
NewAmsterdam Pharma is a company listed under the stock ticker NAMS (NL).
Executives
View the org chart displaying its 22 main executives
Most searched biographies at NewAmsterdam Pharma
- Michael Davidson, Chief Executive Officer and Director
- Sander Van Slootweg, Director
- Nicholas Downing, Director
Popular executive movements at NewAmsterdam Pharma
- Juliette Audet, who was Director, is promoted to Chief Business Officer (posted on April 2 2024).
- William Lewis has joined the company as Chairman of the Board (posted on January 9 2024).
- Ian Somaiya has joined the company as Chief Financial Officer (posted on October 24 2023).
Click here to view some more movements at NewAmsterdam Pharma
Create your alert
to follow the executive moves at NewAmsterdam Pharma.
Pharmaceuticals
NewAmsterdam Pharma has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by NewAmsterdam Pharma
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease | NewAmsterdam Pharma Company
- NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients | NewAmsterdam Pharma Company N.V.
- View more press releases Close
Social media about NewAmsterdam Pharma
- NewAmsterdam Pharma on Wikipedia, Google News & Yahoo Finance
- NewAmsterdam Pharma on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Michael Davidson 
Call NewAmsterdam Pharma at +31 35...
